Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Long before it's time for hospice care, many people with serious illness can benefit from palliative care but don’t realize it. Sometimes referred to as “comfort care,” palliative care is a specialized approach to the treatment of patients with a serious or life-threatening illness. Palliative care has helped Deadra Gladden get her life back through symptom management and support from Samaritan Healthcare & Hospice, Marlton, N.J.
In May of 2014 Deadra, age 28, was in the hospital, feeling hopeless and in excruciating pain due to lupus, a disease she has been battling for over half her young life. Deadra's doctors told her family it was time to call hospice. But after consulting with a nurse from Samaritan Healthcare and Hospice, a palliative care team was brought in instead.
To view the multimedia release go to:
http://www.multivu.com/players/English/7429131-moments-of-life-by-hospice/
Nuelle™, a sexual wellness and intimate care company focused on delivering groundbreaking solutions made specifically for women, announces today its Indiegogo campaign to raise awareness and funding for the company’s first product launch Fiera® Arouser for Her™.
In the US, roughly 46% of all American women, aged 18 – 70 have a sexual concern. Among committed couples, intimacy is important for both the health of the relationship and personal wellbeing. Sex, however, is often a tough subject to broach with partners, health care professionals and friends alike. Through its partnership with Indiegogo, Nuelle aims to normalize the conversation about women’s sexual wellbeing and the impact on quality of life, while educating couples about Fiera® Arouser for Her™ and its proven technology to scientifically enhance arousal and desire, naturally.
Co-created with women and healthcare professionals to bring back excitement to connect sexually with her partner, Nuelle’s Fiera® Arouser for Her™ is the first wearable intimacy enhancer used in advance of a sexual experience that is proven to ignite arousal and increase desire among women. In a study (after four weeks of using Fiera), 87% of women said they felt “in the mood” for sex and 83% enjoyed engaging in sex.*
To view the multimedia release go to:
http://www.multivu.com/players/English/7750851-nuelle-indiegogo-fiera-arouser-for-her/
Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine.
Seqirus is now shipping to the US all influenza vaccines in its portfolio, including Fluad™ (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent™ (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine) in advance of the peak of influenza season.
“Seqirus is proud to be a major contributor to the prevention and control of influenza by offering healthcare providers and pharmacists with a range of clinically proven, innovative vaccination options that help protect people against the debilitating effects of the disease,” said Brent MacGregor, Senior Vice President, Commercial Operations. “We are committed to being an early and reliable supplier of our influenza vaccines to help ensure that appropriate patients have plenty of time to get their annual immunization.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7902351-seqirus-franchise-shipment/
Ascensia Diabetes Care today announced the availability of the CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) in the United Kingdom, one of the next steps in the evolution of self-monitoring of blood glucose. As part of the system, the CONTOUR®NEXT ONE meter and CONTOUR®DIABETES app seamlessly connect, which makes capturing blood glucose results effortless for people with diabetes. The system enables patterns and trends to be revealed that can help people understand their diabetes, and may help to improve diabetes management.
The system features an easy-to-use wireless-enabled smart meter that links to a smart mobile device via Bluetooth® connectivity. The CONTOUR®NEXT ONE meter gives immediate feedback and also seamlessly connects to the CONTOUR®DIABETES app, which collects, stores and analyses patient blood glucose results received from the meter. The app combines these results with other data recorded by the user, to provide detailed information about their condition that can help them understand how their everyday lives may impact their blood glucose readings, including alerts for critical high or critical low readings. Through the app, meter users can also share with their healthcare professional the reports of their blood glucose results and patterns, either in advance or on the day of their appointment, helping to create more informed discussions.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7954951-contour-next-one-bgms-ascensia/
Money 20/20 Conference – Broadridge Customer Communications, North America’s premier customer communications company and part of Broadridge Financial Solutions, today launched the Broadridge Communications Cloud℠ at Money 20/20. Using patented technology and analytics, the Broadridge Communications Cloud connects Broadridge’s current network of more than 900 brands, 138 million recipient households, and five billion annual communications, to a network of 10 digital channels consumers already use, including Amazon, Dropbox and Evernote.
Companies in banking, brokerage, credit card, healthcare, insurance, mutual fund, telecommunications, utilities and other consumer-facing industries can use the Broadridge Communications Cloud to distribute essential customer communications. These forms of communications include bills, statements, healthcare explanations of benefits, regulatory and tax documents, and can now be shared through any of 10 digital channels, based on consumer preference.
To view the multimedia release go to:
http://www.multivu.com/players/English/7950951-broadridge-communications-cloud/
Sandaire, an international family investment office with a base in Singapore and Delancey, a UK focused real estate advisory company, today launch Mount Kendal in Asia. Mount Kendal is a new collaboration between Delancey and Sandaire and will be focused on delivering bespoke UK real estate investment advice to Asian investors and international family offices.
Together, the two firms bring over 45 years of experience to Mount Kendal, which was established to deliver acquisition strategies and innovative asset management initiatives. Ultimately Mount Kendal seeks to create and protect value across a myriad of multi-sector, single asset or asset portfolio investments; from office, retail, residential and logistics; to healthcare, education, equity reversions and more.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8088051-sandaire-delancey-launch-mount-kendal/
Grammy and Emmy award winner, and Tony award nominee, the multi-talented musician, singer and actor Harry Connick, Jr. and his wife of 24 years and former model, Jill Connick, recently marked the fifth anniversary of Jill’s recovery from breast cancer. As Jill credits timely screening and early detection for being a cancer survivor today, she is joining Harry to share their experience and to raise awareness of another cancer for which timely screening is critical: colon cancer.* Their efforts will support The New 50, a public education campaign sponsored by Exact Sciences, that debuts today during Colorectal Cancer Awareness Month. The initiative aims to encourage people 50 and older to talk with their healthcare provider about screening, including the modern, noninvasive options that can fit into any schedule of this busy, on-the-go “new 50” generation.
To view the multimedia release go to:
https://www.multivu.com/players/English/8280451-harry-and-jill-connick-colon-cancer-screening-the-new-50/
Results from a new national survey released today indicate that our lifestyle exacerbates the challenge of trying to lose weight, making it more difficult than ever for adults to do so. Findings further suggest that adults who are trying to lose weight need a new approach that’s compatible with how we live today.
Specifically, most healthcare professionals and a majority of U.S. adults say losing weight is harder today than it was for previous generations because of the busy, modern lifestyle of Americans (77% of primary care physicians or PCPs, 81% of pharmacists, 62% U.S. adults). In fact, approximately seven in 10 healthcare professionals say it’s harder for Americans today to lose weight compared to just 10 years ago (69% of PCPs, 73% of pharmacists), and the vast majority believe Americans need to take a new approach to weight loss that fits with today’s modern lifestyle (89% of PCPs, 95% of pharmacists).
To view the multimedia release go to:
https://www.multivu.com/players/English/8215151-the-truth-about-weight-loss-national-survey/
Clean, soft sheets are now less than 60 seconds away. After more than three years in development, Peel Away Labs’ 100% waterproof multilayer sheet makes it easy for consumers and healthcare personnel to change the bed sheets. By simply pulling down the sheet from one corner, a soiled sheet is “peeled away” in seconds to reveal a fresh one underneath. The fitted sheets are 32% softer than traditional sheets and have a breathable membrane allowing for a cooler night’s sleep.
Health experts say sheets in the home should be changed every seven to 10 days due to bacteria, fungi, animal dander, pollen and other microbes found on beds. Peelaways’ fitted sheets are available for the home, with sizes from crib to king, ranging from $15.99-$39.99. Peelaways is especially ideal for home caregivers taking care of someone with incontinence issues or children who wet the bed, to new moms who are constantly changing their newborn’s mattress protectors. Peelaways offers sheets with five to seven layers per package. With one Peelaways multilayer sheet, people can sleep on a clean and healthy sheet for up to two months.
To view the multimedia release go to:
https://www.multivu.com/players/English/8361451-peel-away-labs-peelaways-disposable-fitted-sheets/
